Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Floor Backes

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group StudyBarbara M Norquist, Mark F Brady, Maria I Harrell, et al.
Gynecologic Oncology|February 22, 2025
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort studyPaulina J Haight, Marilyn Sanchez, Samantha M Thomas, et al.
Gynecologic Oncology|May 25, 2023
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group studyAaron M Praiss, Austin Miller, Judith Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neuAmanda N Fader, Dana M Roque, Eric Siegel, et al.
Gynecologic Oncology|March 8, 2025
Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)Allan Covens, Helen Q Huang, Bradley J Monk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2015
Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group StudyPaul J Goodfellow, Caroline C Billingsley, Heather A Lankes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 27, 2025
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort studyAngeles Alvarez Secord, Victoria Bae-Jump, Floor Backes, et al.
Gynecologic Oncology|August 15, 2025
Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerabilityBradley R Corr, Samantha M Thomas, Paulina J Haight, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient TumorsBrian M Slomovitz, David Cibula, Weiguo Lv, et al.
The New England Journal of Medicine|March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2017
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group StudyBarbara M Norquist, Mark F Brady, Maria I Harrell, et al.
Gynecologic Oncology|February 22, 2025
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort studyPaulina J Haight, Marilyn Sanchez, Samantha M Thomas, et al.
Gynecologic Oncology|May 25, 2023
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group studyAaron M Praiss, Austin Miller, Judith Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neuAmanda N Fader, Dana M Roque, Eric Siegel, et al.
Gynecologic Oncology|March 8, 2025
Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)Allan Covens, Helen Q Huang, Bradley J Monk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2015
Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group StudyPaul J Goodfellow, Caroline C Billingsley, Heather A Lankes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 27, 2025
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort studyAngeles Alvarez Secord, Victoria Bae-Jump, Floor Backes, et al.
Gynecologic Oncology|August 15, 2025
Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerabilityBradley R Corr, Samantha M Thomas, Paulina J Haight, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient TumorsBrian M Slomovitz, David Cibula, Weiguo Lv, et al.
The New England Journal of Medicine|March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Pageof 6